Regeneron Pharmaceuticals REGN
Regeneron Pharmaceuticals Q2 FY24: revenue $3.5B; diluted EPS $12.41
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0001804220-24-000028
Key figures from this report
These are the numbers Regeneron Pharmaceuticals reported for Q2 FY24, the quarter ended Jun 30, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.
- Revenue$3.5BNo year-earlier figure tagged10-Q income statement, on EDGAR
- Net income$1.4BNo year-earlier figure tagged10-Q income statement, on EDGAR
- Diluted EPS$12.41No year-earlier figure tagged10-Q income statement, on EDGAR
- Cash and cash equivalents$1.9BNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
- Cash from operations$354.0MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Zoetis ZTS public float $69.2B, Jun 30, 2025
- Idexx Laboratories IDXX public float $42.9B, Jun 30, 2025
- Alnylam Pharmaceuticals ALNY public float $42.6B, Jun 30, 2025
- Bristol Myers Squibb BMY public float $94.2B, Jun 30, 2025
- Gilead Sciences GILD public float $103.2B, Jun 30, 2025